Page 36 - GPD-3-2
P. 36

Gene & Protein in Disease                                                       Review of CAR-T in ADs



               doi: 10.1056/NEJMoa1106152                         Value and affordability of CAR T-cell therapy in the United
            92.  Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy:   States. Bone Marrow Transplantat. 2020;55(9):1706-1715.
               The efficacy and  toxicity balance.  Curr Hematol Malig      doi: 10.1038/s41409-020-0956-8
               Rep. 2023;18(2):9-18.
                                                               98.  Műzes  G,  Sipos  F.  CAR-based  therapy  for  autoimmune
               doi: 10.1007/s11899-023-00687-7                    diseases: A novel powerful option. Cells. 2023;12(11):1534.
            93.  Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART      doi: 10.3390/cells12111534
               cell imaging: Paving the way for success in CART cell
               therapy. Mol Ther Oncol. 2021;20:625-633.       99.  Atilla E, Kilic P, Gurman G. Cellular therapies: Day by day,
                                                                  all the way. Transfus Apher Sci. 2018;57(2):187-196.
               doi: 10.1016/j.omto.2021.03.003
                                                                  doi: 10.1016/j.transci.2018.04.019
            94.  Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells
               expressing CD19 chimeric antigen receptors for acute   100. Bao C, Gao Q, Li LL, et al. The application of nanobody in
               lymphoblastic leukaemia in children and young adults: A phase   CAR-T therapy. Biomolecules. 2021;11(2):238.
               1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
                                                                  doi: 10.3390/biom11020238
               doi: 10.1016/s0140-6736(14)61403-3
                                                               101. Ye B, Hu Y, Zhang M, Huang H. Research advance in lipid
            95.  Mei  H, Jiang  H, Wu  Y,  et al. Neurological  toxicities  and   nanoparticle-mRNA  delivery  system  and  its  application
               coagulation disorders in the cytokine release syndrome   in CAR-T cell therapy. Zhejiang Xue Xue Bao Yi Xue Ban.
               during CAR-T therapy. Br J Haematol. 2018;181(5):689-692.  2022;51(2):185-191.
               doi: 10.1111/bjh.14680                             doi: 10.3724/zdxbyxb-2022-0047
            96.  Gupta S, Simic M, Sagan SA,  et al. CAR-T cell-mediated   102. Bozza M, De Roia A, Correia MP,  et al. A  nonviral,
               B-cell depletion in central nervous system autoimmunity.   nonintegrating DNA nanovector platform for the safe, rapid,
               Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200080.  and persistent manufacture of recombinant T cells. Sci Adv.
               doi: 10.1212/nxi.0000000000200080                  2021;7(16):eabf1333.
            97.  Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA.      doi: 10.1126/sciadv.abf1333










































            Volume 3 Issue 2 (2024)                         15                              doi: 10.36922/gpd.2851
   31   32   33   34   35   36   37   38   39   40   41